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5-HT2A/C receptorsThe purpose of this study was to determine the effects of alstonine, an indole alkaloid with putative antipsy-
chotic effects, on working memory by using the step-down inhibitory avoidance paradigm and MK801-induced
working memory deﬁcits in mice. Additionally, the role of serotonin 5-HT2A/C receptors in the effects of alsto-
nine on mouse models associated with positive (MK801-induced hyperlocomotion), negative (MK801-induced
social interaction deﬁcit), and cognitive (MK801-induced working memory deﬁcit) schizophrenia symptoms
was examined. Treatment with alstonine was able to prevent MK801-induced working memory deﬁcit, indicat-
ing its potential beneﬁt for cognitive deﬁcits now seen as a core symptom in the disease. Corroborating previ-
ously reported data, alstonine was also effective in counteracting MK801-induced hyperlocomotion and social
interaction deﬁcit. Ritanserin, a 5-HT2A/C receptor antagonist, prevented alstonine's effects on these three be-
havioral parameters. This study presents additional evidence that 5-HT2A/C receptors are central to the antipsy-
chotic-like effects of alstonine, consistently seen in mouse models relevant to the three dimensions of
schizophrenia symptoms.DOPAC, dihydroxyphenylace-
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Although schizophrenia was ﬁrst described as dementia (praecox
dementia), cognitive deﬁcits are increasingly regarded as the core symp-
tom of the disease and, unfortunately, the one where treatment failure
is more evident (Insel, 2010). More speciﬁcally, problemswith working
memory (WM) are seen to be one aspect of cognitive processes that
have a substantial and broad impact on the daily activities of schizo-
phrenic patients (Silver et al., 2003).
Almost 60 years after the introduction of the ﬁrst antipsychotic in
pharmacotherapy, clinical trials still clearly show that improved treat-
ments for psychosis are sorely needed (Insel, 2010). Moreover, the supe-
riority of the second-generation antipsychotics (SGA) is now under
question (Anil Yağcioğlu, 2007; Hamann et al., 2003). The modest and
controversial effects of antipsychotics on cognitive deﬁcits and negative
symptoms, combined with the associated unwanted side effects, result
in discontinued treatments (Lieberman et al., 2005) reinforcing the need
for drugswith a better proﬁle. Overall, the clinical data suggest that signif-
icant improvement in the treatment of schizophrenia is likely to require
drugs with an innovative mechanism of action (Gründer et al., 2009).Wehave reported the antipsychotic-like effects of alstonine, a putative
antipsychotic, which consistently differ from the effects of known drugs
in various mouse models (de Moura Linck et al., 2008; Elisabetsky and
Costa-Campos, 2006; Linck et al., 2011). Alstonine is an indole alkaloid
present in plant species traditionally used in Nigeria to treat mental ill-
nesses, and its mechanism of action remains unclear (Costa-Campos
et al., 1998). Importantly, D2 blockade does not appear to play an impor-
tant role in alstonine's antipsychotic-like effects, whereas its anxiolytic ef-
fects depend on serotonin 5-HT2A/C receptor (Costa-Campos et al., 2004).
Alstonine-induced increases in serotonin (5-HT) and 5-hydroxyindole
acetic acid (5-HIAA) inmouse frontal cortex and striatum further suggest
its modulatory effect on this neurotransmitter system (Linck et al., 2011).
The validity of the glutamatergic hypothesis of schizophreniawas no-
tably reinforced by the observation that NMDA antagonists (such as
phencyclidine and ketamine) induce schizophrenia-like symptoms in
normal volunteers and worsen symptoms in schizophrenic patients
(Javitt, 2010). Accordingly, animal models based on NMDA receptor an-
tagonists have been given preference over the older dopamine based ro-
dentmodels, especially because the latter display the full array (negative,
positive and cognitive) of symptoms observed in schizophrenia (Large,
2007).
Theﬁrst purpose of this studywas to evaluate the effects of alstonine
on MK801-induced working memory deﬁcit in mice. Additionally, we
further examined the role of 5-HT2A/C receptors in alstonine's effects
on mouse models associated with positive, negative and cognitive
schizophrenia symptoms.
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2.1. Animals
Experiments were performed with male (CF1) adult albino mice
(40–45 g) obtained from Fundação Estadual de Produção e Pesquisa
em Saúde (FEPPS) at 2 months of age. Mice were maintained in our
own animal facility under controlled environmental conditions (22±
1 °C, 12-h light/dark cycle, free access to food [Nuvilab CR1] and
water), for at least two weeks before the experiments.
The studywas approvedby theUniversity ethics committee (approval
#18236); all procedureswere carried out in accordancewith institutional
policies on experimental animal handling.
2.2. Drugs
Clozapine and sulpiride were purchased from Sigma Chemical Co.
(St. Louis, MO, USA);MK801 (dizocilpine) and ritanserinwere fromRe-
search Biochemicals International (Natick,MA, USA). Clozapine and sul-
piride were solubilized in HCl (1 N), and the pH adjusted to 6.0 with
NaOH 1 N; ritanserin was dissolved in 10% dimethyl sulfoxide
(DMSO); all other drugs were diluted in distilled water. Pilot studies
showed that DMSO 10% did not affect any of the behavioral tests (data
not shown); hence, saline was used as a blank control. Treatments
were administered intraperitoneally (0.1 mL/10 g of body weight).
With the same dose and timing alstonine does not alter locomotion or
social interaction (Costa-Campos et al., 2004; de Moura Linck et al.,
2008).
2.3. Isolation and identiﬁcation of alstonine
Alstonine hydrochloride used in this study was isolated from the
fruit rinds of P. nitida Stampf Th. et H.Dur. (Apocynaceae). The separa-
tions used pH-zone-reﬁning counter-current chromatography as pre-
viously detailed (Okunji et al., 2005, 2011). Brieﬂy, the experiment
was performed with a two-phase solvent system composed of methyl
tert-butyl ether (MtBE)–acetonitrile–water (2:2:3, v/v), where
triethylamine (TEA) was added to the upper organic stationary
phase as a retainer, and hydrochloric acid (HCl) to the aqueous mo-
bile phase as an eluter. The sample solution was prepared by dissol-
ving 15.0 g of alkaloid fraction of the methylene chloride extract of
P. nitida in 100 mL of a phase mixture consisting of equal volumes
of each phase. The separation was initiated by completely ﬁlling the
column with the stationary phase (LC pump) before loading the sam-
ple; the mobile phase was pumped into the column at 2 mL/min
while the column was rotated at 834 rev/min in the combined head
to tail elution mode (Shinomiya et al., 1993). The absorbance of the
eluate was continuously monitored at 280 nm and 4 mL fractions
were collected. The pH of each eluted fraction was measured with a
pH meter and fractions were dried using a Speed Vac. Identiﬁcation
of pH-zone reﬁning counter-current chromatography pure fractions
was carried out by using thermospray liquid chromatography-mass
spectrometry (LC-MS) and by TLC co-elution experiments with refer-
ence alstonine samples provided by InterCEDD, Nsukka, Nigeria. The
purity of the isolated alstonine sample was 98%.
2.4. Does alstonine improve working memory deﬁcit?
Step-down inhibitory avoidance: The protocol was adapted from
Barros et al. (2005). Mice were habituated to the dimly lit experimen-
tation room for at least 30 min before the procedure. The inhibitory
avoidance training apparatus was a plastic box of 30×30×40 cm,
with a ﬁxed platform (5×5×4 cm) at the center of the grid ﬂoor.
Mice were individually placed on the platform, and the latency to
step-down (four paws on the grid) was automatically recorded in
training and test sessions. In the training session, upon steppingdown, the mouse received a 0.3 mA scrambled foot shock for 5 s.
Test sessions were performed 10 s later, with the same procedure ex-
cept that no shock was administered after stepping down; a 300-s
cut-off time was set for stepping down.
2.4.1. Working memory assessment
Mice (n=14–17) were treated with saline, clozapine (2 mg/kg),
sulpiride (10 mg/kg) or alstonine (0.5 or 1 mg/kg). Thirty minutes
after treatment mice were subjected to the training session.
2.4.2. MK801-induced working memory deﬁcit
Mice (n=23–31) were likewise treated with saline, clozapine,
sulpiride or alstonine; 30 min later mice received a second treatment
with either saline or MK801 (0.05 mg/kg). The step-down training
session was performed 30 min after the last treatment.
2.5. Are the effects of alstonine dependent on 5-HT2A/C receptors?
In order to evaluate the involvement of 5-HT2A/C on alstonine
antipsychotic-like effects mice were pre-treated with the 5-HT2A/C re-
ceptor antagonist ritanserin before behavioral tests. Drug doses and
administration schedules were based on Su et al. (2007), as well as
on pilot studies showing that ritanserin was devoid of effects per se.
2.5.1. MK801-induced working memory deﬁcit
After habituation mice (n=9–17) received saline or the 5-HT2A/C
antagonist ritanserin (0.1 mg/kg); 10 min later animals were treated
with saline or alstonine 1 mg/kg, followed 30 min later by a third ad-
ministration of either saline or MK801 (0.05 mg/kg). Working memory
was tested as described above, 30 min after the last treatment.
2.5.2. MK801-induced social withdrawal
Method was adapted from Rung et al. (2005). Mice were acclima-
tized to a reversed 12-h light cycle (lights on at 20:00 h), housed at
8/cage (familiar group) for 2 weeks before the experiments. Mice
were randomly assigned to groups (n=8–13 pairs) that received sa-
line or ritanserin (0.1 mg/kg), and 10 min later were treated with sa-
line or alstonine 1 mg/kg. Social withdrawal was induced with
MK801 (0.3 mg/kg), given 30 min after the second saline or ritanserin
treatment (Rung et al., 2005). Experiments were performed 30 min
after the last treatment, in a faintly lit room (red bulb, 40W); the social
interaction apparatus (test box) consisted of a topless transparent
acrylic box (25×20×20 cm). Forty-eight and 24 h before the test
mice were individually submitted to 10 min habituation sessions in
the test box. Then, on the test day, mice were allocated to selected
pairs so that the two animals came from unfamiliar groups (different
home cages), had matching body weights, and received the same drug
treatment. The behavior of each pair was video-recorded in the test
box for 10 min; the time spent in social interaction (snifﬁng and groom-
ing the partner, following, mounting, and crawling under or over the
partner)was later analyzed by a trained observer, blind to experimental
groups, using the software The Observer® XT5.0 (Noldus Information
Technology, Wageningen, The Netherlands). Passive contact (sitting or
lying with bodies in contact) was not considered as social interaction.
2.5.3. MK801-induced hyperlocomotion
The method was adapted from Ninan and Kulkarni (1998). Activity
cages (45×25×20 cm, Albarsch Electronic Equipment, Porto Alegre,
Brazil) were equipped with three parallel photocells, which automati-
cally recorded the number of crossings. Mice (n=6–9) were treated
with saline or ritanserin (0.1 mg/kg), and 10 min later with saline or
alstonine 1 mg/kg; 30 min after the second treatment the animals re-
ceived saline or MK801 (0.25 mg/kg). Mice were individually placed in
the activity cages 30 min after the last administration, and locomotion
was recorded from the 5th minute for 10 min (ﬁrst 5 min considered
as exploratory behavior).
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Step-down inhibitory avoidance results are expressed as median±
interquartile ranges; other data are presented as mean±standard
error of the mean (SEM). Data were analyzed with SPSS for Windows,
version 17. The results from step-down avoidance failed to satisfy the
assumptions for normality and homogeneity of variance; therefore,
nonparametric analyseswere applied.Wilcoxon's testwas used to com-
pare training and test latencies within groups, while Kruskal–Wallis/
Mann–Whitney U was used to compared the latencies among the
groups. All other data did satisfy the assumptions of normality and ho-
mogeneity of variance, and were analyzed by one-way analysis of vari-
ance (ANOVA). The analysis focused on the effects of ritanserin on
MK801-induced social withdrawal and hyperlocomotion where the ef-
fects of alstonine in these models were previously established. SNK
post-hoc test was used where appropriate to analyze differences be-
tween the groups. Statistical signiﬁcance was set at pb0.05.
3. Results
Neither alstonine, nor ritanserin, clozapine, sulpiride or MK801
0.05 mg/kg signiﬁcantly altered locomotion at the doses used in the
study (data not shown).
3.1. Does alstonine improve working memory deﬁcit?
As previously reported (Barros et al., 2005), with the adopted
training paradigm consistently longer test latencies were observed
in all groups, conﬁrming that working memory can be reliably
assessed using this procedure. As can be seen in Fig. 1A, neither alsto-
nine, clozapine nor sulpiride modiﬁed working memory (comparable
training [H(4)=3.13] and test session [H(4)=1.76]), with test session
latencies signiﬁcantly longer than training ones (pb0.05 Wilcoxon).Fig. 1. Alstonine effects on inhibitory avoidance working memory (n=14–17) (A) and MK
closed dots (●) test latencies. Lines represent median. **=pb0.01 test×training (WilcoxonMK801 effectively induced working memory deﬁcit (Fig. 1B).
Mann–Whitney showed reduced test latencies in the saline group
treated with MK801 in comparison with controls (H(5)=19.2,
p=0.018); accordingly, in this group no signiﬁcant differences exist
between training and test session latencies (Wilcoxon, p=0.76). Clo-
zapine, sulpiride and alstonine effectively prevented the MK801-in-
duced working memory deﬁcit (pb0.01, Wilcoxon for test×training
session latencies in all treatment groups).3.2. Are the effects of alstonine dependent on 5-HT2A/C receptors?
3.2.1. Working memory deﬁcit
The alstonine preventive effect against MK801-induced working
memory deﬁcit (Wilcoxon, p=0.001) was abolished by pretreatment
with ritanserin (Wilcoxon, p=0.13). Training session latencies were
comparable [H(5)=4.18] (Fig. 2A).3.2.2. Social withdrawal
One-way ANOVA revealed a signiﬁcant difference between groups
(F5,96=8.68) (Fig. 2B). SNK indicated that MK801 clearly reduced so-
cial interaction time (pb0.01) in relation to control. SNK showed that
pretreatment with ritanserin modiﬁed the effects of alstonine (but
not MK801 per se) on social interaction (pb0.05); while alstonine
prevented the effect of MK801 on social interaction (pb0.05), this ef-
fect is abolished by pre-administration of ritanserin (pN0.05).3.2.3. Hyperlocomotion
As shown in Fig. 2C, therewas a signiﬁcant effect of treatments in lo-
comotor activity (F5,54=9.83). SNK revealed that, as expected, MK801
signiﬁcantly (pb0.01) increased crossings in relation to control. Al-
though alstonine prevented the MK801-induced hyperlocomotion
(pb0.05), pre-treatment with ritanserin abolished this effect (pN0.05).801-induced deﬁcit (n=23–31) (B). Open dots (○) represent training latencies and
). #=pb0.01 compared to saline test session latency (Kruskal Wallis/Mann–Whitney).
Fig. 2. Ritanserin modiﬁes alstonine effects on working memory deﬁcit (n=9–17) (A), social withdrawal (n=8–13 pairs) (B), and hyperlocomotion (n=6–8) (C). 2A open dots
(○) represent training latencies and closed dots (●) test latencies (sec). Lines represent median (sec). *=pb0.05, **=pb0.01 test×training (Wilcoxon). 2B columns represent
time spent on social interaction (sec, mean±S.E.M). 2 C columns represent crossings (mean±S.E.M); **=pb0.01 compared with control, and #=pb0.05 compared to sal/sal/MK.
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Though effective treatments are not available (Harvey, 2009; Keefe
et al., 2007), several authors advocate a more careful clinical assess-
ment of cognitive deﬁcits in schizophrenics (Keefe et al., 2007; Keefe
and Fenton, 2007; Wykes et al., 2007), since the former are currently
considered a key component of schizophrenia (Barch, 2005). Special
attention has been given to working memory deﬁcits, directly associat-
ed with troublesome daily tasks, communication, social relations, and
executive activities (Hyman and Fenton, 2003; Silver et al., 2003).
In order to assess working memory we used the inhibitory avoid-
ance paradigm with a 10 s training-test interval (Bianchin et al.,
1999). Results show consistently longer test sessions indicating that
memory is reliably evaluated, and also that a signiﬁcant deﬁcit (am-
nesia) is induced by MK801 with this protocol. Treatment withalstonine was effective in preventing the MK801-induced deﬁcit. It
is noteworthy that animal models based on NMDA antagonists such
as MK801 are regarded as having reasonable face validity and predic-
tive value (Large, 2007; Rujescu et al., 2006).
We further show that pre-treatment with ritanserin reliably
blocked the effects of alstonine on these mouse models of cognitive
deﬁcit (MK801-induced working memory deﬁcit), positive (MK801-
induced hyperlocomotion) and negative (MK801-induced social with-
drawal) schizophrenia symptoms. This body of results is consistent
with the hypothesis that 5-HT2A/C receptors are involved in alstonine's
antipsychotic-like proﬁle, and consistent with its effects on mouse
models of anxiety (Costa-Campos et al., 2004). Indeed, atypical anti-
psychotics act as 5-HT2A/C receptor antagonists and/or inverse ago-
nists (Meltzer and Massey, 2011), and this serotonergic modulation
is thought to be crucial for the purported advantages of these
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evidence for the role of serotonin in alstonine's mechanism of action
is that serotonin and 5-HIAA levels were found to be increased in
mouse frontal cortex and striatum after alstonine administration
(Linck et al., 2011).
Even though the neuropathological basis of schizophrenia remains
to be elucidated, accumulating evidence indicates that hypofunction
of NMDA receptors does occur in this disease (Belforte et al., 2010;
Kristiansen et al., 2007; Paz et al., 2008). It is to be expected that altered
NMDA function would imply meaningful changes in various neuro-
transmission systems (including GABA, 5-HT, DA) contributing to the
complex patterns of behavioral alterations seen in schizophrenic pa-
tients (Kristiansen et al., 2007). It is relevant to this discussion that
NMDA blockade has been shown to lead to a 5-HT2A-dependent in-
crease in serotonergic transmission (López-Gil et al., 2007; Martin
et al., 1998). Similar modulation is illustrated by the ﬁnding that the in-
creased ﬁring rate in prefrontal cortex glutamatergic neurons induced
byMK801 (0.05 mg/kg, i.p., as in this study) can be prevented by ritan-
serin (Labonte et al., 2009).
In 2009, natural product-derived drugs represented 50% of all ap-
proved newdrugs;moreover, between 2005 and 2007, of the 13 natural
products-derived drugs approved in theUSA 5were the ﬁrstmember of
a new class (Li and Vederas, 2009). While this clearly shows the role of
natural products in pharmaceutical innovation, it is arguable that natu-
ral compounds identiﬁed through ethnopharmacological analysis of
traditional uses may be especially useful in the case of illnesses with
an ill-deﬁned pathophysiology (Patwardhan, 2005), such as schizo-
phrenia (Elisabetsky, 2007). Considering the pitfalls of currently avail-
able medication, the coherence of the animal data presented here
with claims of therapeutic beneﬁt in mentally ill patients is promising.
A clear characterization of alstonine's mechanism of action is therefore
warranted and necessary, including in vitro functional binding to clarify
the exact nature of the interaction between alstonine and serotonin re-
ceptor subtypes.
5. Conclusion
Alstonine is an indole alkaloid with an antipsychotic-like proﬁle in
mouse models; it has been identiﬁed as the main component in plant-
based formulations used to treat mentally ill patients in Africa. We
here show that alstonine prevents MK801-induced working memory
deﬁcit in mice. Additionally, ritanserin blocked the effects of alstonine
on mouse models of cognitive deﬁcit, positive and negative symptoms
in schizophrenia. In agreementwith current understanding of the phar-
macodynamic basis of atypical antipsychotic action, 5-HT2A/C receptors
are implicated in alstonine's effects.
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